Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07596134 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC

Study acronym: HLP1-1331
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later May 25, 2028 → Oct 15, 2028
See other at-risk trials from Zhejiang University

Record History

  1. Start date: May 25, 2026 to Oct 15, 2026 Primary completion pushed from May 25, 2028 to Oct 15, 2028 · Trial sites expanded: 4 → 7 locations · Completion pushed from May 25, 2029 to Oct 15, 2029 · 3 more Show 6 more changesShow less
    • Primary completion pushed from May 25, 2028 to Oct 15, 2028
    • Trial sites expanded: 4 → 7 locations
    • Completion pushed from May 25, 2029 to Oct 15, 2029
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: 9 to 8
    • Study description shortened, about 5 words
  2. Primary endpoint(s) modified Secondary endpoints: 6 to 9 · Study title shortened, about 11 wordsv2 Show 2 more changesShow less
    • Secondary endpoints: 6 to 9
    • Study title shortened, about 11 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Zhejiang University
149 trials monitored
See 4 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
Multimodal Thermal Therapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone for systemically untreated unresectable hepatocellular carcinoma (HCC)
Trial Details
NCT Number NCT07596134
Lead Sponsor Zhejiang University
Conditions Unresectable Hepatocellular Carcinoma (HCC)
Enrollment 166 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov